These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30359121)

  • 21. Impact of EMPA-REG OUTCOME
    Naing S; Poliyedath A; Khandelwal S; Sigala T
    Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
    Nguyen E; Coleman CI; Nair S; Weeda ER
    J Diabetes Complications; 2018 Feb; 32(2):210-215. PubMed ID: 29157870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.
    Kappel BA; Lehrke M; Schütt K; Artati A; Adamski J; Lebherz C; Marx N
    Circulation; 2017 Sep; 136(10):969-972. PubMed ID: 28874423
    [No Abstract]   [Full Text] [Related]  

  • 26. Preventing cardiovascular events with empagliflozin: at what cost?
    Naci H; Basu S; Yudkin JS
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):931. PubMed ID: 26590682
    [No Abstract]   [Full Text] [Related]  

  • 27. In Patients with Type 2 Diabetes and CV Disease, Empagliflozin Reduces CV and All-Cause Mortality.
    Ebell MH
    Am Fam Physician; 2016 Mar; 93(5):410. PubMed ID: 26926979
    [No Abstract]   [Full Text] [Related]  

  • 28. ACP Journal Club. In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years.
    Shekelle P
    Ann Intern Med; 2016 Jan; 164(2):JC2. PubMed ID: 26784492
    [No Abstract]   [Full Text] [Related]  

  • 29. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
    Verma S; Mazer CD; Al-Omran M; Inzucchi SE; Fitchett D; Hehnke U; George JT; Zinman B
    Circulation; 2018 Jan; 137(4):405-407. PubMed ID: 29133602
    [No Abstract]   [Full Text] [Related]  

  • 30. [Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME].
    Scheen AJ
    Rev Med Liege; 2019 Apr; 74(4):185-191. PubMed ID: 30997967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Empagliflozin also protects high risk patients].
    Arnheim K
    MMW Fortschr Med; 2016 Jun; 158(11):82. PubMed ID: 27271430
    [No Abstract]   [Full Text] [Related]  

  • 32. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Zinman B; Wanner C; Lachin JM; Fitchett D; Bluhmki E; Hantel S; Mattheus M; Devins T; Johansen OE; Woerle HJ; Broedl UC; Inzucchi SE;
    N Engl J Med; 2015 Nov; 373(22):2117-28. PubMed ID: 26378978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
    Vettor R; Inzucchi SE; Fioretto P
    Diabetologia; 2017 Mar; 60(3):395-398. PubMed ID: 28074254
    [No Abstract]   [Full Text] [Related]  

  • 34. Letter by Tsuda Regarding Article, "Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial".
    Tsuda K
    Circulation; 2020 Mar; 141(9):e100-e101. PubMed ID: 32119586
    [No Abstract]   [Full Text] [Related]  

  • 35. SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.
    Wanner C; Marx N
    Diabetologia; 2018 Oct; 61(10):2134-2139. PubMed ID: 30132035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk].
    Scheen AJ
    Rev Med Liege; 2015 Nov; 70(11):583-9. PubMed ID: 26738271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms linking empagliflozin to cardiovascular and renal protection.
    Perrone-Filardi P; Avogaro A; Bonora E; Colivicchi F; Fioretto P; Maggioni AP; Sesti G; Ferrannini E
    Int J Cardiol; 2017 Aug; 241():450-456. PubMed ID: 28395981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?].
    Scheen AJ; Paquot N
    Rev Med Liege; 2018 Jan; 73(1):43-50. PubMed ID: 29388411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
    Dailey GE
    Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.